

July 2019, Volume 81, Number 1

## CONTENTS

### Continuing Medical Education

**CME** 1

Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention

Papillomaviruses and Merkel cell polyomavirus

*Christopher T. Haley, MD, Uyen Ngoc Mui, MD, Ramya Vangipuram, MD, Peter L. Rady, MD, PhD, and Stephen K. Tyring, MD, PhD*

21

Answers to CME examination (Identification No. JA0719), July 2019 issue of the *Journal of the American Academy of Dermatology*

22

**CME examination**

**CME** 23

Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention

Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein–Barr virus

*Uyen Ngoc Mui, MD, Christopher T. Haley, MD, Ramya Vangipuram, MD, and Stephen K. Tyring, MD, PhD*

41

Answers to CME examination (Identification No. JB0719), July 2019 issue of the *Journal of the American Academy of Dermatology*

42

**CME examination**

**CME** 43

Benign oral mucosal lesions: Clinical and pathological findings

*Mayra B. C. Maymone, DDS, MD, DSc, Robert O. Greer, DDS, ScD, Lauren K. Burdine, Anh Dao-Cheng, Samantha Venkatesh, Priya Cherukuri Sahitya, Alexandre C. Maymone, DDS, Jeffery Kesecker, DDS, and Neelam A. Vashi, MD*

57

**CME examination**

58

Answers to CME examination (Identification No. JC0719), July 2019 issue of the *Journal of the American Academy of Dermatology*

Clinical image courtesy of John McDowell, DDS.

Copyright © 2019 by the American Academy of Dermatology, Inc. *Journal of the American Academy of Dermatology* (ISSN: 0190-9622), is published monthly by Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices.

**POSTMASTER:** Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA.

**CME** **59** Premalignant and malignant oral mucosal lesions: Clinical and pathological findings  
*Mayra B. C. Maymone, DDS, MD, DSc, Robert O. Greer, DDS, ScD, Jeffery Kesecker, DDS, Priya Cherukuri Sahitya, BA, Lauren K. Burdine, BA, Anh-Dao Cheng, BA, Alexandre C. Maymone, DDS, and Neelam A. Vashi, MD*

**71** Answers to CME examination (Identification No. JD0719), July 2019 issue of the *Journal of the American Academy of Dermatology*

**72** CME examination

**Letter from the Editor** **73** Accepted manuscripts and galley proofs  
*Dirk M. Elston, MD*

**A Clinician's Perspective** **74** Eosinophilic dermatosis of hematologic malignancy: Reality bites  
*Warren R. Heymann, MD*

**Original Articles** **76** North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations  
 Part I: Diagnosis, evaluation, and the use of complementary and procedural management

**Bottom line: Grading of the available evidence is reviewed in this article and recommendations for optimal disease management are provided.**

*Ali Alikhan, MD (Co-chair), Christopher Sayed, MD (Co-chair), Afsaneh Alavi, MD, MSc, Raed Alhusayen, MD, Alain Brassard, MD, Craig Burkhart, MD, Karen Crowell, MLIS, Daniel B. Eisen, MD, Alice B. Gottlieb, MD, PhD, Iltefat Hamzavi, MD, Paul G. Hazen, MD, Tara Jaleel, MD, Alexa B. Kimball, MD, MPH, Joslyn Kirby, MD, MEd, MS, Michelle A. Lowes, MBBS, PhD, Robert Micheletti, MD, Angela Miller, CCRP, CWCA, Haley B. Naik, MD, MHSc, Dennis Orgill, MD, and Yves Poulin, MD*

**91** North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Part II: Topical, intralesional, and systemic medical management

**Bottom line: Available evidence is graded and recommendations for management including a therapeutic algorithm is provided.**

*Ali Alikhan, MD (Co-chair), Christopher Sayed, MD (Co-chair), Afsaneh Alavi, MD, MSc, Raed Alhusayen, MD, Alain Brassard, MD, Craig Burkhart, MD, Karen Crowell, MLIS, Daniel B. Eisen, MD, Alice B. Gottlieb, MD, PhD, Iltefat Hamzavi, MD, Paul G. Hazen, MD, Tara Jaleel, MD, Alexa B. Kimball, MD, MPH, Joslyn Kirby, MD, MEd, MS, Michelle A. Lowes, MBBS, PhD, Robert Micheletti, MD, Angela Miller, CCRP, CWCA, Haley B. Naik, MD, MHSc, Dennis Orgill, MD, and Yves Poulin, MD*

- 102** A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation
- Bottom line:** The recombinant zoster vaccine should be administered to all psoriasis and psoriatic arthritis patients >50 years old and to those <50 years old at increased risk.
- Emily Baumrin, MD, Abby Van Voorhees, MD, Amit Garg, MD, Steven R. Feldman, MD, PhD, and Joseph F. Merola, MD, MMSc*
- 111** Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil
- Bottom line:** Eruptive squamous atypia can resolve in two-thirds of patients receiving intralesional 5-fluorouracil monotherapy, and in the remainder, it can resolve with addition of an adjunct treatment (topical steroid or 5-fluorouracil, cryotherapy, or acitretin). No lesions treated with intralesional 5-fluorouracil required surgery.
- Sybil Keena T. Que, MD, MPH, Leigh A. Compton, MD, PhD, and Chrysalynne D. Schmults, MD, MSCE*
- 123** Vancomycin-associated drug-induced hypersensitivity syndrome
- Bottom line:** Vancomycin-attributable drug-induced hypersensitivity syndrome may be associated with a higher burden of renal involvement—occurring in up to 75% of cases. Surveillance for this complication is indicated, and further characterization may inform prognosis.
- Lauren M. Madigan, MD, and Lindy P. Fox, MD*
- 129** Characterization of chronic urticaria and associated conditions in a large population of adolescents
- Bottom line:** Recognition of the association between atopy and chronic spontaneous urticaria might provide pathogenic insights and improve patient management.
- Yossi Rosman, MD, Alon Y. Hershko, MD, PhD, Keren Meir-Shafir, MD, Ron Kedem, Idit Lachover-Roth, MD, Yoseph A. Mekori, MD, and Ronit Confino-Cohen, MD*
- 136** Predictors of mucosal melanoma survival in a population-based setting
- Bottom line:** Because of the poor prognosis for all stages of mucosal melanoma, dermatologists should consider incorporating examination of the oropharynx and genitalia in the full body skin examination.
- Lisa Altieri, MD, Megan Eguchi, MPH, David H. Peng, MD, MPH, and Myles Cockburn, PhD*

- 143** Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
- Bottom line:** This study confirmed the effectiveness of dupilumab in daily practice but demonstrated a higher frequency of conjunctivitis and eosinophilia compared with clinical trial results.
- Sarah Faiz, MD, Jonathan Giovannelli, MD, PhD, Céline Podevin, MSc, Marie Jachiet, MD, Jean-David Bouaziz, MD, PhD, Ziad Reguiai, MD, Audrey Nosbaum, MD, PhD, Audrey Lasek, MD, Marie-Christine Ferrier le Bouedec, MD, Aurélie Du Thanh, MD, PhD, Nadia Raison-Peyron, MD, Florence Tetart, MD, Anne-Bénédicte Duval-Modeste, MD, Laurent Misery, MD, PhD, François Aubin, MD, PhD, Anne Domp martin, MD, PhD, Cécile Morice, MD, Catherine Droitcourt, MD, PhD, Angèle Soria, MD, PhD, Jean-Philippe Arnault, MD, PhD, Juliette Delaunay, MD, Emmanuel Mahé, MD, PhD, Marie-Aleth Richard, MD, PhD, Amélie Schoeffler, MD, Jean-Philippe Lacour, MD, PhD, Edouard Begon, MD, Amélie Walter-Lepage, MD, Anne-Sophie Dillies, MD, Sandrine Rappelle-Duruy, MD, Stéphane Barete, MD, PhD, Nathalia Bellon, MD, Nathalie Bénéton, MD, Aude Valois, MD, Sébastien Barbarot, MD, PhD, Julien Sénéchal, MD, PhD, and Delphine Staumont-Sallé, MD, PhD, on behalf of the Groupe de Recherche sur l'Éczéma aTopique (GREAT), France*
- 152** Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis
- Bottom line:** Over 500,000 people living in the United States are estimated to have chronic urticaria, most of whom are women and adults aged 40-59 years, who might benefit from seeking treatment from a dermatologist.
- Sara Wertenteil, BA, Andrew Strunk, MA, and Amit Garg, MD*
- 157** Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis
- Bottom line:** These results should be incorporated into the interpretation of patch testing results and clinical decision making in patients with atopic dermatitis.
- Molly Stout, MD, and Jonathan I. Silverberg, MD, PhD, MPH*
- 163** Sexual dysfunction in men taking systemic dermatologic medication: A systematic review
- Bottom line:** We identified evidence for sexual adverse effects in patients taking 11 systemic dermatologic medications. Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
- George A. Zakhem, MD, MBA, Julia E. Goldberg, MD, MBA, Catherine C. Motosko, MD, Brandon E. Cohen, MD, and Roger S. Ho, MD, MS, MPH*
- 173** Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
- Bottom line:** Drug survival was lower for secukinumab than ixekizumab, albeit that performance was higher for bio-naïve patients with both drugs. Ixekizumab may be a suitable option especially in patients who have previously failed on other biologics, whereas secukinumab may be most useful for bio-naïve patients.
- Alexander Egeberg, MD, PhD, Lars Erik Bryld, MD, PhD, and Lone Skov, MD, PhD, DMSc*

- 179** Rituximab therapy in patients with bullous pemphigoid:  
A retrospective study of 20 patients  
**Bottom line:** Patients had fewer adverse events and infections in the period after taking rituximab than before, suggesting an acceptable safety profile. Rituximab is an alternative treatment for recalcitrant bullous pemphigoid.  
*Maxim Polansky, MD, Rachel Eisenstadt, MD, Taryn DeGrazia, BS, Xiwen Zhao, MPH, Yuan Liu, PhD, and Ron Feldman, MD, PhD*
- 187** Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom  
**Bottom line:** In this study, adult patients with atopic dermatitis, especially those with uncontrolled disease, reported a significant burden on health, health-related quality of life, productivity, activities, and health care.  
*Laurent Eckert, PhD, Shaloo Gupta, MSc, Abhijit Gadkari, PhD, Puneet Mahajan, PhD, and Joel M. Gelfand, MD*
- 196** A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis  
**Bottom line:** This randomized, double-blind phase 1 trial showed a favorable safety profile for M1095, as well as promising efficacy. The M1095 nanobody offers the potential to neutralize multiple targets in psoriasis.  
*Danka Svecova, MD, PhD, Martin W. Lubell, MD, Florence Casset-Semanaz, MSc, Harald Mackenzie, MBChB, Roland Grenningloh, PhD, and James G. Krueger, MD*

**Dermatologic Surgery**

- 204** Comparison of surgical margins for lentigo maligna versus melanoma in situ  
**Bottom line:** Subclinical extension is similar for lentigo maligna, melanoma in situ, and invasive melanoma. Wide local excision of all noninvasive melanomas on the trunk and extremities should include a 9-mm surgical margin. Head and neck lesions may require wider margins.  
*Joy H. Kunishige, MD, Linda Doan, MD, David G. Brodland, MD, and John A. Zitelli, MD*
- 213** Use of 5-0 Fast Absorbing Gut versus 6-0 Fast Absorbing Gut during cutaneous wound closure on the head and neck: A randomized evaluator-blinded split-wound comparative effectiveness trial  
**Bottom line:** There are no significant differences in wound cosmesis using 5-0 versus 6-0 Fast Absorbing Gut sutures on the head or neck. Surgeons may safely use whichever they prefer.  
*Aunna Pourang, MD, Milene K. Crispin, MD, Ashley K. Clark, MD, April W. Armstrong, MD, MPH, Raja K. Sivamani, MD, MS, AP, and Daniel B. Eisen, MD*

**Dermatopathology**

- 219** Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes  
**Bottom line:** Combined checkpoint blockade of LAG-3 and TIGIT might be of therapeutic value in melanoma.  
*Woo Jin Lee, MD, PhD, Ye Jin Lee, MD, Myoung Eun Choi, MD, Kyung A. Yun, MSc, Chong Hyun Won, MD, PhD, Mi Woo Lee, MD, PhD, Jee Ho Choi, MD, PhD, and Sung Eun Chang, MD, PhD*

---

<b>Review</b>	<b>228</b>	<p>Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus</p> <p><b>Bottom line: The aim of this consensus was to provide practical recommendations for the management of nail psoriasis in patients without or with mild skin psoriasis.</b></p> <p><i>Dimitrios Rigopoulos, MD, PhD, Robert Baran, MD, PhD, Soumiya Chiheb, MD, PhD, Carlton Ralph Daniel III, MD, PhD, Nilton Di Chiacchio, MD, PhD, Stamatis Gregoriou, MD, PhD, Chander Grover, MD, DNB, Eckart Haneke, MD, PhD, Matilde Iorizzo, MD, PhD, Marcel Pasch, MD, PhD, Bianca Maria Piraccini, MD, PhD, Phoebe Rich, MD, Bertrand Richert, MD, PhD, Natalia Rompoti, MD, Adam I. Rubin, MD, Archana Singal, MD, FAMS, Michela Starace, MD, PhD, Antonella Tosti, MD, PhD, Ioanna Triantafyllopoulou, MD, and Martin Zaia, MD</i></p>
<hr/>		
<b>Research Letters</b>	<b>241</b>	<p>Cutaneous extranodal natural killer/T-cell lymphoma: Clinical implications of whole blood Epstein-Barr virus DNA</p> <p><i>Se Jin Oh, MD, Ji-Hye Park, MD, Jong Hee Lee, MD, PhD, and Dong-Youn Lee, MD, PhD</i></p>
	<b>243</b>	<p>Masculine norms and sunscreen use among adult men in the United States: A cross-sectional study</p> <p><i>Costner McKenzie, BA, Alfred W. Rademaker, PhD, and Roopal V. Kundu, MD</i></p>
	<b>245</b>	<p>Access to dermatology services at free medical clinics: A nationwide cross-sectional survey</p> <p><i>Victoria Madray, BS, Sarvani Ginjupalli, BS, Osama Hashmi, MPH, Richard W. Sams, MD, MA, J. Aaron Johnson, PhD, and Benjamin Stoff, MD, MA</i></p>
	<b>246</b>	<p>Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center</p> <p><i>Vieri Grandi, MD, Roberto Maglie, MD, Emiliano Antiga, MD, PhD, Margherita Vannucchi, MD, Chiara Delfino, MD, Irene Lastrucci, MD, Susanna Gunnella, MD, Stefania Ciolli, MD, Lavinia Quintarelli, MD, Daniela Massi, MD, PhD, Marzia Caproni, MD, PhD, and Nicola Pimpinelli, MD, PhD</i></p>
	<b>249</b>	<p>Rhinophyma is associated with alcohol intake</p> <p><i>Julie Second, MD, François Severac, MD, Adrien Paix, and Bernard Cribier, MD, PhD</i></p>
	<b>250</b>	<p>Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case—control study</p> <p><i>Outi Varpuluoma, MD, PhD, Jari Jokelainen, MSc, Anna-Kaisa Försti, MD, PhD, Miia Turpeinen, MD, PhD, Markku Timonen, MD, PhD, Laura Huilaja, MD, PhD, and Kaisa Tasanen, MD, PhD</i></p>
	<b>253</b>	<p>Sun exposure risks in athletes who were recipients of solid organ and bone marrow transplants</p> <p><i>María V. de Gálvez, PhD, MD, Jose M. Ruiz Sánchez, MD, María Navarrete-de Gálvez, MD, José Aguilera, PhD, Magdalena de Troya-Martín, PhD, MD, Francisco Rivas-Ruiz, PhD, and Enrique Herrera-Ceballos, PhD, MD</i></p>

- 255** Liposuction-like sclerotherapy technique: A deep approach to superficial lymphatic malformations  
*Huajie Wang, MD, Xinkui Guo, MD, Qiang Liu, MD, Na Liu, MD, Xin He, MD, Yuping Peng, MD, Hongfen Lv, MD, Xiaoqian Zhou, MD, and Ya Gao, MD*
- 257** Mobile teledermatology for melanoma detection: Assessment of the validity in the framework of a population-based skin cancer awareness campaign in northern Italy  
*Simone Cazzaniga, MS, Emanuele Castelli, BSc, Anna Di Landro, MD, Marco Di Mercurio, MD, Gianlorenzo Imberti, MD, Gustavo Andrea Locatelli, MD, Francesca Raponi, MD, Pamela Vezzoli, MD, Daniele Gambini, MD, Giovanni Damiani, MD, Alberto Zucchi, MD, and Luigi Naldi, MD*
- 260** Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy  
*Amit Mittal, MD, Vaishali Mittal, BA, Gauri Panse, MD, Jennifer N. Choi, MD, Bernice Y. Kwong, MD, and Jonathan S. Leventhal, MD*
- 263** Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial  
*Sharon Rose, MD, Shelbi Jim On, MD, Wayne Fuchs, MD, Chen Chen, MD, Robert Phelps, MD, Davida Kornreich, MD, Madelaine Haddican, MD, Giselle Singer, BS, Vicky Wong, BA, Danielle Baum, RN, Anjali Vekaria, MD, Matthew Gagliotti, BS, Ruiqi Huang, PhD, Mayte Suárez-Fariñas, PhD, Sharon F. Terry, MA, and Mark Lebwohl, MD*
- 265** Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review  
*Rachel G. Casseres, BA, Jared S. Kahn, MS, BS, Min Ji Her, PharmD, and David Rosmarin, MD*
- 267** Inpatient dermatology consultations and the July effect: A retrospective cohort study  
*Sheena Tsai, MD, MPH, Harib H. Ezaldeen, MD, Rosalynn R. Z. Conic, MD, Miesha Merati, DO, and Jeffrey F. Scott, MD*
- 269** The most common causes of burnout among US academic dermatologists based on a survey study  
*Deborah N. Dorrell, BA, Steven R. Feldman, MD, PhD, and William Wei-ting Huang, MD, MPH*
- 270** Real-world drug survival of ixekizumab for psoriasis  
*Erica B. Lee, BS, Deeti J. Pithadia, BS, Kelly A. Reynolds, BA, Shivani P. Reddy, MD, Alexander Egeberg, MD, PhD, and Jashin J. Wu, MD*
- 273** Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study  
*Tiago Torres, MD, PhD, Anna Balato, MD, Curdin Conrad, MD, PhD, Andrea Conti, MD, Paolo Dapavo, MD, Paulo Ferreira, MD, Francesca Gaiani, MD, Luíz Leite, MD, Piergiorgio Malagoli, MD, Pedro Mendes-Bastos, MD, Matteo Megna, MD, Francesco Messina, MD, Alessia Nidegger, MD, Giulia Odorici, MD, Stefano Piaserico, MD, PhD, Francesca Prignano, MD, Simone Ribero, MD, Federica Ricceri, MD, Annalisa Tonini, MD, Joana Valério, MsC, and Andrea Chiricozzi, MD*

	<b>275</b>	Tracking changes in nailfold capillaries during dermatomyositis treatment <i>Yahya Argobi, MD, and Gideon P. Smith, MD, MPH, PhD</i>
	<b>276</b>	Pharmacy costs of medications for the treatment of onychomycosis in the United States <i>Eric J. Yang, BS, and Shari R. Lipner, MD, PhD</i>
	<b>278</b>	Clinical differences in pediatric and adult <i>Malassezia</i> folliculitis: Retrospective analysis of 321 cases over 9 years <i>Yi-Chiun Tsai, MD, Jen-Yu Wang, MD, Yu-Hung Wu, MD, and Yen-Jen Wang, MD</i>
	<b>280</b>	Use of complementary and alternative medicine by patients with psoriasis <i>Emily C. Murphy, BS, Dillon Nussbaum, BS, Ronald Prussick, MD, and Adam J. Friedman, MD</i>
<hr/>		
<b>Dermatoethics Consultation</b>	<b>284</b>	The emboldened medical student: Ethical dilemmas in a university clinic <i>Aamir Hussain, MSIV, and Jane M. Grant-Kels, MD</i>
<hr/>		
<b>Health Policy &amp; Practice</b>	<b>287</b>	Future considerations for clinical dermatology in the setting of 21st century American policy reform: Corporatization and the rise of private equity in dermatology <i>Sailesh Konda, MD, Joseph Francis, MD, Kiran Motaparathi, MD, and Jane M. Grant-Kels, MD, Group for Research of Corporatization and Private Equity in Dermatology</i>
	<b>297</b>	Navigating the landscape of core outcome set development in dermatology <b>Bottom line: Cochrane Skin—Core Outcome Set Initiative provides methodologic support for dermatology-specific core outcome set initiatives to ensure high quality across core outcome sets in dermatology.</b> <i>Cecilia A. C. Prinsen, PhD, Phyllis I. Spuls, MD, PhD, Jan Kottner, PhD, Kim S. Thomas, PhD, Christian Apfelbacher, PhD, Joanne R. Chalmers, PhD, Stefanie Deckert, MPH, Masutaka Furue, PhD, Louise Gerbens, PhD, Jamie Kirkham, PhD, Eric L. Simpson, PhD, Murad Alam, MD, Katrin Balzer, PhD, Dimitri Beeckman, PhD, Viktoria Eleftheriadou, PhD, Khaled Ezzedine, MD, Sophie E. R. Horbach, PhD, John R. Ingram, MD, PhD, Alison M. Layton, MD, Karsten Weller, PhD, Thomas Wild, MD, Albert Wolkerstorfer, PhD, Hywel C. Williams, DSc, and Jochen Schmitt, MD, MPH</i>
<hr/>		
<b>Beyond JAAD</b>	<b>306</b>	Beyond JAAD July 2019: Articles of interest to dermatologists from the nondermatologic literature <i>Andrew Bronin, MD, Robert Phelps, MD, and Robert Sidbury, MD</i>
<hr/>		
<b>Correction</b>	<b>310</b>	Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. <i>J Am Acad Dermatol.</i> 2019;80(2):321-39

<b>JAAD Game Changers</b>	<b>311</b>	JAAD Game Changers: Pemphigus and hematologic malignancies: A population-based study of 11,859 patients <i>Eden Lake, MD</i>
	<b>312</b>	JAAD Game Changers: The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP) <i>Eden Lake, MD</i>

**JAAD ONLINE**

**Available at <http://www.jaad.org>**

<b>Clinical Pearl</b>	<b>e1</b>	An easy technique for the measurement calibration of a universal serial bus dermatoscope <i>Mahesh Mathur, MD, DCP, Prakash Acharya, MBBS, MD, and Alina Karki, MBBS, MD</i>
<b>Therapeutic Pearl</b>	 <b>e3</b>	Disposable paper cup as a cheap and ready-to-use stencil for spot cryo treatment <i>Karalikkattil T. Ashique, MBBS, DDVL, PG Dip Med Cosmetology, and Feroze Kaliyadan, MD, DNB, MNAMS, FIMSA</i>
<b>Surgical Pearls</b>	<b>e5</b>	Pull-through inferiorly based island pedicle flap for a conchal bowl defect <i>Paula Fernández-Canga, MD, Eduardo Varas-Meis, MD, and Manuel A. Rodríguez-Prieto, MD</i>
	<b>e7</b>	Simplified approach to the design of rhombic flaps <i>Karsten S. Johnson, DO, Collin M. Blattner, DO, and William Lear, MD</i>
<b>Technology Pearl</b>	<b>e9</b>	Utilization of optical coherence tomography as a noninvasive, bedside imaging technique to identify residual nodular basal cell carcinoma at a well-healed and clinically unidentifiable biopsy site <i>Hao Feng, MD, MHS, Mitalee P. Christman, MD, Jon Holmes, MA, and Roy G. Geronemus, MD</i>
<b>Notes &amp; Comments</b>	<b>e11</b>	Further thoughts on dermatology and equity-owned dermatology practices <i>Richard G. Bennett, MD</i>
	<b>e13</b>	Response to letter to the editor from Bennett and further thoughts on the corporatization of dermatology and private equity—backed dermatology groups <i>Joseph Francis, MD, Sailesh Konda, MD, Kiran Motaparathi, MD, and Jane M. Grant-Kels, MD, Group for Research of Corporatization and Private Equity in Dermatology</i>
	<b>e15</b>	Peristomal pyoderma gangrenosum: An exceedingly rare and overdiagnosed entity? <i>Stephanie T. Le, MD, Jenny Z. Wang, BS, Claire Alexanian, BA, Samantha Ellis, MD, Yocasta C. Martinez-Alvarado, MD, Stephanie Johng, BS, Apra Sood, MD, and Emanuel Maverakis, MD</i>

- e17** Basal cell carcinoma: Additional subtypes and therapeutic advances  
*Philip R. Cohen, MD*
- e19** Reply to: “Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment”  
*Kevin T. Savage, BA, Kelsey S. Flood, MD, Sabrina Popatia, MPH, Nicole M. Golbari, BA, Prerna Salian, MPH, Alexa B. Kimball, MD, MPH, and Martina L. Porter, MD*

**Iotaderma**

- e21** Iotaderma (#305)  
*Robert I. Rudolph, MD, FACP*

To access the current version of the Information for Authors, Transfer of Copyright Form, Authorship Declaration Form, Conflict of Interest Disclosure, and Authors’ Rights Statement, as well as many other pertinent documents, please visit our website at [www.jaad.org/content/auth\\_page](http://www.jaad.org/content/auth_page).

Full text access to *Journal of the American Academy of Dermatology Online* is now available for Academy members and all print subscribers. To activate your online subscription, please visit *Journal of the American Academy of Dermatology Online* by pointing your browser to <http://www.jaad.org>.

**Icon Key**

-  = **CME article**
-  = **Video content available at <http://www.jaad.org>**
-  = **Podcast available at <http://www.aad.org/olc>**
-  = **MOC credits available**

**Early online publication: Articles in press**

The *Journal of the American Academy of Dermatology* posts in-press articles online before they appear in the print edition of the *Journal*. These Articles in Press are available from both the JAAD website ([www.jaad.org](http://www.jaad.org)) and Science Direct ([www.sciencedirect.com](http://www.sciencedirect.com)). To access Articles in Press, simply click the Articles in Press link.

**JAAD Case Reports**

The *Journal of the American Academy of Dermatology* no longer publishes Case Reports. These can now be found in our new open access journal, *JAAD Case Reports*, at <http://www.jaadcasereports.org>.